Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice
Authors:
- Joseph P. ShottJSJoseph P. Shott
- Kent E. KesterKKKent E. Kester
- Patrice DuboisPDPatrice Dubois
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of ResearchVaccine, 2008
- Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trialThe Lancet, 2007
- A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adultsVaccine, 2007
- The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoitesNature, 2006
- Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trialThe Lancet, 2005
- Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialThe Lancet, 2004
- Sporozoite Antigens: Biology and Immunology of the Circumsporozoite Protein and Thrombospondin-Related Anonymous Protein2002
- Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trialThe Lancet, 2001
- Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalariaThe Journal of Infectious Diseases, 2001
- A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalariaNew England Journal of Medicine, 1997